Table 4. Comparison of overall survival between unresected, stage III NSCLC patients treated with systemic therapy, chemotherapy, and concurrent chemoradiotherapy.

	Unadjusted Results		Adjusted Results1
	Hazard ratio (95% CI)	P-value	Hazard ratio (95% CI)	P-value
Systemic therapy only	1.38 (1.26, 1.51)	<0.001*	1.35 (1.22, 1.49)	<0.001*
Radiotherapy only	1.75 (1.61, 1.91)	<0.001*	1.58 (1.44, 1.73)	<0.001*

Abbreviations: NSCLC: non-small cell lung cancer; CRT: Chemoradiotherapy; CI: Confidence interval

^[1] Adjusted hazard ratios (HRs) were estimated from a Cox proportional hazards model adjusting for the following baseline covariates: race, gender, age, region, setting of residence, primary tumor site, grade, laterality, histology, stage (3a or 3b), index year of first therapeutic regimen, number of unique metastatic sites, all cancer metastatic sites at baseline, all comorbidities present at baseline, CCI, tumor marker tests, and predicted performance status.